Literature DB >> 9208376

Dopamine, the prefrontal cortex and schizophrenia.

M B Knable1, D R Weinberger.   

Abstract

Dysfunction of the prefrontal cortex (PFC) in schizophrenia has been suspected based on observations from clinical, neuropsychological and neuroimaging studies. Since the PFC receives a dense dopaminergic innervation, abnormalities of the mesocortical dopamine system have been proposed to contribute to the pathophysiology of schizophrenia. In this review, aspects of the anatomy, physiology and pharmacology of the mesencephalic-frontal cortical dopamine system as they may relate to schizophrenia are described, and evidence for altered dopaminergic neurotransmission in the frontal cortex of schizophrenic patients is presented.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9208376     DOI: 10.1177/026988119701100205

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  67 in total

1.  Synergistically interacting dopamine D1 and NMDA receptors mediate nonvesicular transporter-dependent GABA release from rat striatal medium spiny neurons.

Authors:  A N Schoffelmeer; L J Vanderschuren; T J De Vries; F Hogenboom; G Wardeh; A H Mulder
Journal:  J Neurosci       Date:  2000-05-01       Impact factor: 6.167

Review 2.  Excitation, inhibition, local oscillations, or large-scale loops: what causes the symptoms of schizophrenia?

Authors:  John Lisman
Journal:  Curr Opin Neurobiol       Date:  2011-11-11       Impact factor: 6.627

3.  The role of prefrontal dopamine D1 receptors in the neural mechanisms of associative learning.

Authors:  M Victoria Puig; Earl K Miller
Journal:  Neuron       Date:  2012-06-07       Impact factor: 17.173

4.  DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia.

Authors:  Giuseppe Blasi; Francesco Napolitano; Gianluca Ursini; Paolo Taurisano; Raffaella Romano; Grazia Caforio; Leonardo Fazio; Barbara Gelao; Annabella Di Giorgio; Luisa Iacovelli; Lorenzo Sinibaldi; Teresa Popolizio; Alessandro Usiello; Alessandro Bertolino
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

5.  Probing cortical dopamine function in schizophrenia: what can D1 receptors tell us?

Authors:  Anissa Abi-Dargham
Journal:  World Psychiatry       Date:  2003-10       Impact factor: 49.548

Review 6.  Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia.

Authors:  Jiri Horacek; Vera Bubenikova-Valesova; Milan Kopecek; Tomas Palenicek; Colleen Dockery; Pavel Mohr; Cyril Höschl
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 7.  Event perception: a mind-brain perspective.

Authors:  Jeffrey M Zacks; Nicole K Speer; Khena M Swallow; Todd S Braver; Jeremy R Reynolds
Journal:  Psychol Bull       Date:  2007-03       Impact factor: 17.737

8.  Effect of risperidone versus haloperidol on emotional responding in schizophrenic patients.

Authors:  E Fakra; S Khalfa; D Da Fonseca; N Besnier; P Delaveau; J M Azorin; O Blin
Journal:  Psychopharmacology (Berl)       Date:  2008-06-25       Impact factor: 4.530

9.  Effects of smoking abstinence, smoking cues and nicotine replacement in smokers with schizophrenia and controls.

Authors:  Jennifer W Tidey; Damaris J Rohsenow; Gary B Kaplan; Robert M Swift; Amy B Adolfo
Journal:  Nicotine Tob Res       Date:  2008-06       Impact factor: 4.244

10.  Prefrontal cognitive dysfunction is associated with tobacco dependence treatment failure in smokers with schizophrenia.

Authors:  Taryn G Moss; Kristi A Sacco; Taryn M Allen; Andrea H Weinberger; Jennifer C Vessicchio; Tony P George
Journal:  Drug Alcohol Depend       Date:  2009-05-17       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.